Evidence map›Paper›PMID 38593217›Full record

ArticleBlood advances2024

Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.

Johannes Lübke, Alicia Schmid, Deborah Christen, Hanneke N G Oude Elberink, Lambert F R Span, Marek Niedoszytko, Aleksandra Gorska, Magdalena Lange, Karoline V Gleixner, Emir Hadzijusufovic and 36 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors at 20 institutions in 13 countries.

Johannes LübkeDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0000-0003-0767-1504
Alicia SchmidDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Deborah ChristenDepartment of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0003-2839-5983
Hanneke N G Oude ElberinkDepartment of Allergology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-2844-2196
Lambert F R SpanDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Marek NiedoszytkoDepartment of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Aleksandra GorskaDepartment of Allergology, Medical University of Gdańsk, Gdańsk, Poland.
Magdalena LangeDepartment of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland.ORCID 0000-0002-6967-1393
Karoline V GleixnerDivision of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Emir HadzijusufovicDivision of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-7409-4204
Alex StefanUniversity Clinic for Hematology and Oncology, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
Irena Angelova-FischerDepartment of Dermatology and Venereology, Allergy Center, Kepler University Hospital, Johannes Kepler University, Linz, Austria.
Roberta ZanottiDepartment of Medicine, Section of Hematology, Verona University Hospital, Verona, Italy.
Massimiliano BonifacioDepartment of Medicine, Section of Hematology, Verona University Hospital, Verona, Italy.
Patrizia BonadonnaAllergy Unit, Verona University Hospital, Verona, Italy.
Khalid ShoumariyehDepartment of Medicine I, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Nikolas von BubnoffDepartment of Medicine I, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID 0000-0001-9593-8947
Sabine MüllerDepartment of Dermatology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Cecelia PerkinsStanford Cancer Institute, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.
Chiara ElenaHematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Luca MalcovatiHematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.ORCID 0000-0002-1460-1611
Hans HagglundDivision of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Mattias MattssonDivision of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Roberta ParenteDivision of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
Judit VarkonyiDepartment of Hematology, Semmelweis University, Budapest, Hungary.
Anna Belloni FortinaDepartment of Medicine, Pediatric Dermatology Unit, University of Padova, Padova, Italy.
Francesca CaroppoDepartment of Medicine, Pediatric Dermatology Unit, University of Padova, Padova, Italy.ORCID 0000-0003-3583-0816
Knut BrockowDepartment of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0002-2775-3681
Alexander ZinkDepartment of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0001-9313-6588
Christine BreynaertKU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group and MASTeL, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-7368-1068
Toon LevenKU Leuven Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group and MASTeL, University Hospitals Leuven, Leuven, Belgium.
Akif Selim YavuzDivision of Hematology, Istanbul Medical School, University of Istanbul, Istanbul, Turkey.
Michael DoubekDepartment of Internal Medicine - Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Vito SabatoDepartment of Immunology-Allergology-Rheumatology, Faculty of Medicine and Health Sciences, University of Antwerp and Antwerp University Hospital, Antwerpen, Belgium.
Tanja SchugDepartment of Dermatology and Venereology, University Hospital Graz, Graz, Austria.
Karin HartmannDivision of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.ORCID 0000-0002-4595-8226
Massimo TriggianiDivision of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.ORCID 0000-0001-7318-2093
Jason GotlibStanford Cancer Institute, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.
Olivier HermineFrench Reference Center for Mastocytosis, Hospital Necker, Assistance Publique Hôpitaux de Paris, Imagine Institute, University Paris Descartes, Paris, France.
Michel ArockFrench Reference Center for Mastocytosis, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, University Paris Sorbonne, Paris, France.
Hanneke C Kluin-NelemansDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-2617-9427
Jens PanseDepartment of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.ORCID 0000-0001-6316-3112
Wolfgang R SperrDivision of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Peter ValentDivision of Hematology & Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-0456-5095
Andreas ReiterDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Juliana SchwaabDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Heidelberg University · DEGdańsk Medical University · PLMedical University of Vienna · ATUniversity Medical Center Groningen · NLUniversity of Freiburg · DEUniversity of Verona · ITKU Leuven · BEPoliclinico San Matteo Fondazione · ITRWTH Aachen University · DEStanford University · USTechnical University of Munich · DEUniversity of Padua · ITUniversity of Salerno · ITUppsala University · SEDélégation Paris 5 · FRGraz University Hospital · ATIstanbul University · TRJohannes Kepler University of Linz · ATMasaryk University · CZSemmelweis University · HU

Funding

Austrian Science Fund FWF P 32470
6 · The paper itself

Abstract

abstractCertain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most specific serum parameter. For differentiation between indolent and advanced SM (AdvSM), the following serum parameters were most relevant: tryptase, alkaline phosphatase, β2-microglobulin, lactate dehydrogenase (LDH), albumin, vitamin B12, and C-reactive protein (P < .001). With regard to subvariants of AdvSM, an elevated LDH of ≥260 U/L was associated with multilineage expansion (leukocytosis, r = 0.37, P < .001; monocytosis, r = 0.26, P < .001) and the presence of an associated myeloid neoplasm (P < .001), whereas tryptase levels were highest in mast cell leukemia (MCL) vs non-MCL (308μg/L vs 146μg/L, P = .003). Based on multivariable analysis, the hazard-risk weighted assignment of 1 point to LDH (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.1-4.0; P = .018) and 1.5 points each to β2-microglobulin (HR, 2.7; 95% CI, 1.4-5.4; P = .004) and albumin (HR, 3.3; 95% CI, 1.7-6.5; P = .001) delineated a highly predictive 3-tier risk classification system (0 points, 8.1 years vs 1 point, 2.5 years; ≥1.5 points, 1.7 years; P < .001). Moreover, serum chemistry parameters enabled further stratification of patients classified as having an International Prognostic Scoring System for Mastocytosis-AdvSM1/2 risk score (P = .027). In conclusion, serum chemistry profiling is a crucial tool in the clinical practice supporting diagnosis and prognostication of SM and its subvariants.

Indexed as

Mastocytosis, SystemicRegistriesAdultAgedBiomarkersFemaleHumansMaleMiddle AgedPrognosisTryptasesBiomarkersTryptases

Identifiers

PMID38593217
PMCPMC11214361
OpenAlexW4394596348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.